Xcelerate Inc. (XCRT)
OTC PINK OTC PINK Primary Summary
Xcelerate, Inc. Announces Funding
MAULDIN, SC / ACCESSWIRE / October 31, 2024 / Xcelerate, Inc. (OTCQB:XCRT) (the "Company"), today announced that it has reached an agreement for business funding to support the growth plan for the ESN Group, a subsidiary of the Company. "Xcelerate's leadership continues to cultivate industry interest in its business model and our 3 pillar business foundation.
Xcelerate, Inc. Announces the Launch of the Ceramedx Tik Tok Skincare Campaign
MAULDIN, SC / ACCESSWIRE / October 23, 2024 / Xcelerate, Inc. (OTCQB:XCRT) today announced that ESN Group, Inc., a subsidiary of Xcelerate, Inc., has launched its' Ceramedx Brand Tik Tok Skincare Campaign, which shall occur during November and December 2024. Jay Kline, President of ESN Group commented "This campaign will be launched in parallel with an enhanced social media/digital marketing launch.
Xcelerate, Inc. Issues Shareholder Update
MAULDIN, SC / ACCESSWIRE / October 15, 2024 / Xcelerate, Inc. 's (OTCQB:XCRT) CEO, Mike O'Shea, today released this letter and shareholder update. Dear Shareholder, During the first six months of 2024, we encountered several impediments to our fundraising and expansion plans.
Xcelerate Inc. (XCRT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Xcelerate Inc. ever had a stock split?
Xcelerate Inc. Profile
| Software Industry | Information Technology Sector | Michael F. O'Shea CEO | OTC PINK Exchange | 98401T105 CUSIP |
| US Country | 12 Employees | - Last Dividend | 25 May 2004 Last Split | - IPO Date |
Overview
Xcelerate Inc. is a dynamic company dedicated to pioneering developments in the medical technology sector. Originally founded as Union Dental Holdings, Inc., the company underwent a strategic transformation, changing its name to Xcelerate Inc. to better reflect its expanded focus and mission. Since its incorporation in 1996 and based out of Mauldin, South Carolina, Xcelerate Inc. specializes in acquiring engineering patents and innovative technologies, which it then applies to early-stage medical technology companies. It plays a crucial role in supplying these cutting-edge solutions to controlled clinical care settings. Through this process, Xcelerate Inc. not only contributes to the trial and testing of new medical technologies but also facilitates their practical application, ensuring a seamless end-to-end development process within the controlled medical technology field.
Products and Services
- Acquisition and Application of Engineering Patents:
Xcelerate Inc. focuses on identifying promising engineering patents and groundbreaking technologies that can revolutionize the healthcare sector. By acquiring these patents, Xcelerate ensures that innovative solutions can be developed and applied effectively within early-stage medical technology companies, fostering advancements in medical treatments and tools.
- Support for Controlled Clinical Care Settings:
The company plays a vital role in supplying newly developed medical technologies to controlled clinical care settings. This strategic focus not only enables the thorough testing and trialing of new medical devices and technologies but also ensures their safe and effective implementation, contributing significantly to the advancement of patient care and clinical outcomes.
- End-to-End Controlled Medical Technology Development:
Offering comprehensive support throughout the entire development process, Xcelerate Inc. is uniquely positioned to facilitate the seamless progression of medical technologies from concept to application. This includes everything from initial acquisition of patents, through development and testing, to final application in clinical settings. Xcelerate's end-to-end solution is designed to streamline the development of medical technologies, ensuring they reach the market efficiently and effectively, fully compliant with the necessary medical standards and regulations.
